vs
Side-by-side financial comparison of Neuphoria Therapeutics Inc. (NEUP) and OFF THE HOOK YS INC. (OTH). Click either name above to swap in a different company.
OFF THE HOOK YS INC. is the larger business by last-quarter revenue ($24.0M vs $15.0M, roughly 1.6× Neuphoria Therapeutics Inc.). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs -0.3%, a 75.4% gap on every dollar of revenue.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
NEUP vs OTH — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $24.0M |
| Net Profit | $11.3M | $-66.7K |
| Gross Margin | — | 12.6% |
| Operating Margin | 79.8% | 1.3% |
| Net Margin | 75.1% | -0.3% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $6.55 | $-0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | $2.3M |
| Total DebtLower is stronger | — | $287.2K |
| Stockholders' EquityBook value | $26.0M | $-610.5K |
| Total Assets | $30.7M | $32.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $2.3M | ||
| Q1 25 | $17.0M | — |
| Q3 25 | — | $287.2K | ||
| Q1 25 | — | — |
| Q3 25 | — | $-610.5K | ||
| Q1 25 | $26.0M | — |
| Q3 25 | — | $32.6M | ||
| Q1 25 | $30.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.5M | $-664.2K |
| Free Cash FlowOCF − Capex | — | $-867.2K |
| FCF MarginFCF / Revenue | — | -3.6% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | 1.02× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-664.2K | ||
| Q1 25 | $11.5M | — |
| Q3 25 | — | $-867.2K | ||
| Q1 25 | — | — |
| Q3 25 | — | -3.6% | ||
| Q1 25 | — | — |
| Q3 25 | — | 0.8% | ||
| Q1 25 | — | — |
| Q3 25 | — | — | ||
| Q1 25 | 1.02× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
